03-21-05

DOCKET

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re Application of:

Brenda F. Baker, et al.

Confirmation No.: 5280

Application No.: 10/701,236

Group Art Unit: 1635

Filing Date: November 4, 2003

Examiner: Not Yet Assigned

SUGAR SURROGATE-CONTAINING OLIGOMERIC COMPOUNDS AND COMPOSITIONS FOR USE IN GENE MODULATION

EXPRESS MAIL LABEL NO: EV325727676US DATE OF DEPOSIT: March 18, 2005

EA35255243PA2

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Dear Sir:

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Pursuant to 37 CFR § 1.56 and in accordance with 37 CFR §§ 1.97-1.98, information relating to the above-identified application is hereby disclosed. Inclusion of information in this statement is not to be construed as an admission that this information is material as that term is defined in 37 CFR § 1.56(b).

冈 In accordance with § 1.97(b), since this Information Disclosure Statement is being filed either within three months of the filing date of the above-identified application, within three months of the date of entry into the national stage of the above identified application as set forth in § 1.491, before the mailing date of a first Office Action on the merits of the above-identified application, or

		before the mailing date of a first Office Action after the filing of request for					
		continued examination under § 1.114, no additional fee is required.					
		In accordance with § 1.97(c), this Information Disclosure Statement is being					
		filed after the period set forth in § 1.97(b) above but before the mailing date of					
		either a Final Action under § 1.116 or a Notice of Allowance under § 1.311, or					
		before an action that otherwise closes prosecution in the application, therefore:					
		Certification in Accordance with § 1.97(e) is attached; or					
		The fee of \$180.00 as set forth in § 1.17(p) is attached.					
		In accordance with § 1.97(d), this Information Disclosure Statement is being					
		filed after the mailing date of either a Final Action under § 1.113 or a Notice					
		of Allowance under § 1.311 but before, or simultaneously with, the payment					
		of the Issue Fee, therefore included are: Certification in Accordance with §					
		1.97(e); and the submission fee of <u>\$180.00</u> as set forth in § 1.17(p).					
		Copies of reference numbers listed on the attached Form PTO-1449 are					
		enclosed herewith.					
	\boxtimes	A copy of reference number 239 on the attached Form PTO 1449 is not					
		required to be submitted pursuant to waiver of 37 CFR § 1.98(a)(2)(i).					
		Copies of references - are not being submitted because					
		they were previously cited by or submitted to the U.S. Patent and					
		Trademark Office in patent application number , filed for					
		which a claim for priority under 35 U.S.C. § 120 has been made in the					
		instant application.					
]	The re	elevance of those listed references which are not in the English language is as					
	follow	/S:					

DOCKET NO.: ISIS-5207

- 3 -

PATENT

There are no listed references which are not in the English language.

Please charge any deficiency or credit any overpayment to Deposit Account No. 23-3050. This form is submitted in duplicate.

Date: March 17, 2005

John A. Harrelson, Jr. Registration No. 42,637

WOODCOCK WASHBURN LLP

One Liberty Place - 46th Floor Philadelphia, PA 19103

Telephone: (215) 568-3100 Facsimile: (215) 568-3439

© 2005 WW



Form PTO-1449 Modified

List of Patent and Publications Cited by Applicant (Use several sheets if necessary)

U.S. Department of Commerce Patent and Trademark Office Docket No. ISIS-5207

Application No. 10/701,236

Applicant

Brenda F. Baker, et al.

Filing Date November 4, 2003 Group 1635

Confirmation No. 5280

U. S. PATENT DOCUMENTS

Examiner Initial		Document No.	Date	Name	Class	Subclass
*	239	2002/0081736 A1	06/27/02	Conroy, et al.	435	455
			<u> </u>		<u> </u>	

FOREIGN PATENT DOCUMENTS

Examiner		Date	Country	Translation	
Initial	Document No.			YES	NO
-					
EXAMINER			DATE CONSIDERED		

^{*} Cited on the PCT Written Opinion dated March 7, 2005 (PCT/US03/35146).